Exit Granules India on rallies: Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "I would recommend that the investor uses this nice bounce to actually switch from Granules India to some other pharmaceutical stock. Basically this is a much smaller marketcap company. Smaller in almost every sense and I believe they have had US FDA issues."

"We have seen a very subdued type of growth but my main reason to see a switch is the valuations. You have the largecap pharma stocks available at reasonable valuations and when the whole market for the US; as their three-fourth of revenues come from the developed markets; they have been showing subdued numbers and this is likely to continue for some time. But when the whole market bounces back, the larger cap companies will do better."

"I personally have investments in Aurobindo Pharma, in Glenmark, these two have come down a lot and they have the potential, when the overall market bounces back to again show rebound. I also like Cipla. I think there is a lot happening out there. The numbers also were good. You can also look at various other stocks like Dr Reddy's Laboratories, Sun Pharmaceuticals. Lupin of course is having some major problems going forward. So I think there is a whole gamut of stocks that you can look to in the largecap stocks with a 2-3 year horizon," she added.